Kristina Burow has served as a member of our board of directors since August 2014. Ms. Burow has served as Managing Director of ARCH Venture Partners, or ARCH, since November 2011 and previously held roles of increasing responsibility at ARCH from August 2002 to November 2011. Ms. Burow currently serves on the board of directors of several biopharmaceutical companies, including Vividion Therapeutics, Inc., Lycera Corp., Sienna Biopharmaceuticals, Inc., Metacrine, Inc., UNITY Biotechnology, Inc., BEAM Therapeutics., AgBiome Inc., and AgTech Accelerator. She previously was a co-founder and member of the board of directors of Receptos, Inc., (acquired by Celgene Corporation). Ms. Burow has participated in a number of other ARCH portfolio companies including Siluria Technologies, Inc., KYTHERA Biopharmaceuticals, Inc. (acquired by Allergan), and Ikaria, Inc. (acquired by Mallinckrodt). Prior to joining ARCH, Ms. Burow was an Associate with the Novartis BioVenture Fund in San Diego and an early employee at the Genomics Institute of the Novartis Research Foundation. Ms. Burow received a BS in Chemistry from the University of California, Berkeley, an MA in Chemistry from Columbia University, and an MBA from the University of Chicago.